FDA 483 - ENDO Pharmaceuticals Solutions, Inc. - January 17, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
ENDO U.S.A Inc. in Cranbury, NJ, a sterile manufacturer, was inspected by the FDA from January 7-17, 2025. The inspection revealed significant deficiencies in laboratory controls, specifically regarding the qualification and use of reference standard Fourier Transform Infrared (FT-IR) spectroscopy data for identifying incoming materials and finished drug products. These issues indicate a failure to ensure the identity, strength, quality, and purity of components and drug products.
ID · 6df7ce6f-8cff-42c6-bf2b-924f87310dd5